EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 July 2010
EMA/COMP/364048/2010 Corr.
Human Medicines Development and Evaluation

Monthly report

Committee for Orphan Medicinal Products (COMP)

7-8 July 2010

The Committee for Orphan Medicinal Products held its 114th plenary meeting on 7-8 July 2010.

Orphan medicinal product designation

The COMP adopted 15 positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission:

For the following medicines the review began on 12 April 2010:

- **16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide** for treatment of medulloblastoma, Biogenera srl (with an active review time of 88 days).
- **Synthetic double-stranded short interfering RNA oligonucleotide directed against pro-opiomelanocortin** for treatment of adrenocorticotropin-dependent Cushing's syndrome, UKR Regulatory Affairs Ltd (with an active review time of 88 days).
- **Tecovirimat** for treatment of cowpox infection, SIGA Pharmaceuticals (Europe) Ltd (adopted via written procedure with an active review time of 96 days).
- **Tecovirimat** for treatment of monkeypox infection, SIGA Pharmaceuticals (Europe) Ltd (adopted via written procedure with an active review time of 96 days).
- **Tecovirimat** for treatment of variola infection, SIGA Pharmaceuticals (Europe) Ltd (adopted via written procedure with an active review time of 96 days).

For the following medicines the review began on 11 June 2010:

- **(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine (tosylate monohydrate salt)** for treatment of mantle cell lymphoma, Merck Sharp & Dohme Limited (adopted via written procedure with an active review time of 36 days).

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

- **(*S*)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-*O*-[alpha-(2", 4", 5", 7"-tetranitro-9"-fluorenylideneaminooxy)propionyl]-1*H*-pyrano[3', 4', 6', 7']indolizino[1,2-beta]-quinoline-3, 14-(4*H*, 12*H*)-dione, hydrochloride** for treatment of hepatocellular carcinoma, TLC Biopharmaceuticals B.V. (with an active review time of 28 days).
- **Ambrisentan** for treatment of idiopathic pulmonary fibrosis, Gilead Sciences International Ltd (with an active review time of 28 days).
- **Ciclosporin** for treatment of moderate or severe closed traumatic brain injury, NeuroVive Pharmaceuticals AB (with an active review time of 28 days).
- **Maytansinoid-conjugated humanised monoclonal antibody against CD56** for treatment of small cell lung cancer, ImmunoGen Europe Limited (with an active review time of 28 days).
- **N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide** for treatment of Friedreich's ataxia, Repligen Europe Limited (with an active review time of 28 days).
- **N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate** for treatment of primary myelofibrosis, Dr Ulrich Granzer (adopted via written procedure with an active review time of 36 days).
- **Pralatrexate** for treatment of Hodgkin's lymphoma, Allos Therapeutics Limited (adopted via written procedure with an active review time of 36 days).
- **Recombinant humanised monoclonal antibody to human Nogo-A protein of the IgG1/kappa class** for treatment of amyotrophic lateral sclerosis, Glaxo Group Limited (with an active review time of 28 days).
- **Recombinant humanised anti-human interleukin-1 beta monoclonal antibody** for treatment of Behçet's disease, XOMA Ireland Ltd (with an active review time of 28 days).

Other information on the orphan medicinal product designation

Lists of questions

The COMP adopted 11 lists of questions on initial applications. These applications will be discussed again at the next COMP meeting prior to adoption of the opinion.

Oral hearings

4 oral hearings took place.

Withdrawals of applications for orphan medicinal product designation

The COMP noted that 4 applications for orphan medicinal product designation were withdrawn.

Detailed information on the orphan designation procedure

An overview of orphan designation procedures since 2000 is provided in Annex 1.

The list of medicinal products for which decisions on orphan designation[1] have been given by the European Commission since the last COMP meeting is provided in Annex 2.

Applications for marketing authorisation for orphan medicinal products

Details of those designated orphan medicinal products that have been subject of a new community marketing authorisation application through the centralised procedure since the last COMP plenary meeting are provided in Annex 3.

Details on the opinions for marketing authorisation for orphan medicinal products adopted by the Committee for Medicinal Products for Human Use (CHMP) can be found in the CHMP monthly report on the Agency's website.

Article 5 (12) of Regulation (EC) No 141/2000 of the European Parliament and of the Council

In line with its responsibility to review whether or not a designated orphan medicinal product still fulfils the designation criteria prior to the granting of a marketing authorisation, the COMP adopted 1 opinion recommending to the European Commission that the following orphan medicinal product be kept in the Community registry of orphan medicinal products:

- **VPRIV (velaglucerase alfa)** for treatment of Gaucher disease, Shire Pharmaceutical Ireland.

Upcoming meetings

- The 115th meeting of the COMP will be held on 7-9 September 2010.

Other matters

The main topics addressed during the meeting related to:

- 3 Protocol Assistance letters were adopted.
- Dr C. Berens, from DG Research, updated the Committee on the latest developments for rare diseases within the Framework Programme 7. The presentation included an update on the projects selected from the last call. The Committee congratulated DG Research for the excellent results from the calls launched and committed to provide feedback on research needs for rare diseases. Additional information on DG research activities can be found at http://ec.europa.eu/research/health/medical-research/rare-diseases/projectsfp7_en.html

Note

This monthly report, together with other information on the work of the European Medicines Agency, can be found on the Agency's website: www.ema.europa.eu

Contact our press officers

Martin Harvey Allchurch or Monika Benstetter

Tel. +44 (0)20 7418 8427, E-mail: press@ema.europa.eu

1 Details of all orphan designations granted to date by the European Commission are entered in the Community Register of Orphan Medicinal Products http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/community-register/html/index_en.htm

Annex 1

Overview for orphan medicinal product designation procedure since 2000

Year	Applications submitted	Applications discussed in reporting year	Positive COMP opinions	Applications withdrawn	Final negative COMP opinions	Designations granted by Commission
2010	97	106	73 (69%)	31 (29%)	2 (2%)	52
2009	164	137	113 (82%)	23 (17%)	1 (1%)	106
2008	119	118	86 (73%)	31 (26%)	1 (1%)	73
2007	125	117	97 (83%)	19 (16%)	1 (1%)	98
2006	104	103	81 (79%)	20 (19%)	2 (2%)	80
2005	118	118	88 (75%)	30 (25%)	0 (0%)	88
2004	108	101	75 (74%)	22 (22%)	4 (4%)	72
2003	87	96	54 (56%)	41 (43%)	1 (1%)	55
2002	80	76	43 (57%)	30 (39%)	3 (4%)	49
2001	83	92	64 (70%)	27 (29%)	1 (1%)	64
2000	72	32	26 (81%)	6 (19%)	0 (0%)	14
Total	**1157**	**1096**	**800 (73%)**	**280 (26%)**	**16 (1%)**	**751**

Annex 2

Medicinal products granted a community designation as orphan medicinal product by the European Commission since the June 2010 COMP monthly report

Active substance	2-methoxymethyl-2-hydroxymethyl-1-azabicyclo [2,2,2] octan-3-one
Sponsor	Aprea AB
Orphan indication	Treatment of acute myeloid leukaemia
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Adrenomedullin
Sponsor	Prof. Dr Stefan Hippenstiel
Orphan indication	Treatment of acute lung injury
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	Bafetinib
Sponsor	Eudax S.R.L.
Orphan indication	Treatment of chronic myeloid leukaemia
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Dexamethasone (40 mg tablet)
Sponsor	Laboratoires C.T.R.S.
Orphan indication	Treatment of multiple myeloma
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	Entinostat
Sponsor	Nexus Onclology Ltd
Orphan indication	Treatment of Hodgkin's lymphoma
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of argininosuccinic aciduria
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of citrullinaemia type 1
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrome)
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of ornithine carbamoyltransferase deficiency
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of carbamoyl-phosphate synthase-1 deficiency
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of hyperargininaemia
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Glyceryl tri-(4-phenylbutyrate)
Sponsor	Hyperion Therapeutics Limited
Orphan indication	Treatment of citrullinaemia type 2
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Maytansinoid-conjugated humanised monoclonal antibody against CD56
Sponsor	ImmunoGen Europe Limited
Orphan indication	Treatment of Merkel cell carcinoma
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate
Sponsor	Aveo Pharma Ltd
Orphan indication	Treatment of renal cell carcinoma
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	Pagibaximab[2]
Sponsor	Omnicare Clinical Research GmbH
Orphan indication	Prevention of sepsis caused by gram positive pathogens in premature infants less than or equal to 34 weeks of gestational age
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	Perifosine
Sponsor	Æterna Zentaris GmbH
Orphan indication	Treatment of multiple myeloma
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Pralatrexate
Sponsor	Choice Pharma Limited
Orphan indication	Treatment of cutaneous T-cell lymphoma
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Pravastatin / zoledronic acid
Sponsor	Prenyl BIO SAS
Orphan indication	Treatment of Hutchinson-Gilford progeria
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

[2] Revised sponsor's name and indication

Active substance	Raloxifene hydrochloride
Sponsor	Consejo Superior de Investigaciones Científicas (CSIC)
Orphan indication	Treatment of hereditary haemorrhagic telangiectasia
COMP opinion date	3 February 2010
Orphan designation date	10 June 2010

Active substance	Recombinant human anti-interferon gamma monoclonal antibody
Sponsor	NovImmune B.V.
Orphan indication	Treatment of haemophagocytic lymphohistiocytosis
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	Rifapentine
Sponsor	Sanofi Aventis
Orphan Indication	Treatment of tuberculosis
COMP opinion date	3 March 2010
Orphan Designation date	9 June 2010

Active substance	Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA
Sponsor	Verius Limited
Orphan indication	Prevention of delayed graft function after renal transplantation
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Active substance	Velaglucerase alfa
Sponsor	Shire Pharmaceuticals Ireland Limited
Orphan indication	Treatment of Gaucher disease
COMP opinion date	3 March 2010
Orphan designation date	9 June 2010

Annex 3

Designated orphan medicinal products that have been subject of a new Community marketing authorisation application under the centralised procedure since the June 2010 COMP monthly report

Active substance	Invented name	Sponsor/applicant	EU designation number	Designated orphan indication
Recombinant inhibitor of human plasma kallikrein	Kalbitor	Dyax s.a. - Belgium	EU/3/02/126	Treatment of angioedema
Mercaptopurine (oral suspension)	Novapurine	Nova Laboratories Limited - UK	EU/3/09/628	Treatment of acute lymphoblastic leukaemia